Context Therapeutics (CNTX) Earnings Analysis
Context Therapeutics (CNTX) has no confirmed upcoming earnings date. Last quarter (2026-03-19) it missed with EPS -0.14 USD vs -0.11 USD est (-27.3%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -1.45.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CNTX next report earnings?
No confirmed upcoming earnings date is currently scheduled for CNTX. This page updates as the calendar is published.
CNTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-19 | -0.14 USD | -0.11 USD | -27.3% | Miss |
| 2025-03-20 | -0.04 USD | -0.05 USD | +20% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
CNTX valuation and analyst view
| Trailing P/E | -1.45 |
|---|---|
| Trailing EPS | -0.42262 USD |
| Price / book | 1.12 |
| Dividend yield | 0.00% |
| Market cap | 0.06B |
| Analyst consensus | Buy (6 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Context Therapeutics (CNTX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CNTX. This page updates as the calendar is published.
Did CNTX beat earnings last quarter?
In its 2026-03-19 report, CNTX posted EPS of -0.14 USD versus a -0.11 USD estimate — a miss of 27.3%.
What is CNTX's earnings track record?
Over the last 2 reported quarters with consensus data, CNTX beat estimates 1 times (50%).
What is CNTX's current P/E ratio and EPS?
CNTX trades at a trailing P/E of -1.45 on trailing EPS of -0.4226240248358443 USD.
What do analysts rate CNTX?
Analyst consensus is "Buy" across 6 ratings (0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell).